Emcure Pharma Block Deal | BC Investments plans 2% stake sale worth ₹493 crore

Global investment firm BC Investments (Bain Capital) is likely set to sell up to 2% of pharmaceutical company Emcure Pharmaceuticals Ltd's total equity through a block deal, with an indicative floor price

of ₹1,296.51 per share.

The price represents a discount of approximately 7% to Emcure Pharma’s closing price of ₹1,394.10 on the NSE on November 17, 2025. The block deal size is estimated at up to ₹493 crore.

Also Read: Emcure Pharma shares decline equity worth ₹574 crore changes hands in block deals

Shares sold through this transaction will have a 90-day lock-in period for further sale. BC Asia held a 6.3% stake in Emcure Pharmaceuticals at the end of Q2 2025.

Second Quarter Results

Emcure Pharmaceuticals reported a 25.1% year-on-year rise in consolidated net profit to ₹243 crore for the quarter ended September 2025, compared with ₹194 crore in the same period last year.

Revenue from operations grew 13.4% to ₹2,269.8 crore from ₹2,001.9 crore in Q2FY25, driven by strong growth across key therapeutic segments and continued momentum in both domestic and international markets.

Also Read: Emcure shares jump 8% on Novo Nordisk tie-up to launch weight-loss drug in India

Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose 25% to ₹475.4 crore from ₹380.3 crore in the year-ago quarter, while EBITDA margin improved to 21% from 19% a year earlier, aided by better product mix and cost efficiencies.

The company said its performance reflected robust traction in its India formulations business and healthy export demand. Emcure continues to maintain a diversified product portfolio across areas including gynaecology, cardiovascular, HIV antivirals, and pain management, and has been expanding its presence in emerging markets through new product launches and regulatory filings.

Shares of Emcure Pharmaceuticals Ltd ended at ₹1,388, up by ₹15.90, or 1.16%, on the BSE today, November 17.